News - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

2001 to 2025 of 2253 results

Overview of biologic regulations in India

26-01-2012

Currently, all biologics in India, including innovative and copy biologics are approved as new drugs,…

Asia-PacificBiotechnologyGenericsRegulation

Deal-making declines as Pharma tighten its belt

26-01-2012

Overall pharmaceutical deal-making activity fell by 18% in 2011 as pharmaceutical companies cut R&D expenditure…

BiotechnologyGlobalLicensingPharmaceutical

Vivalis opens new lab for antibody discovery; posts 112% revenue hike

25-01-2012

French biotech firm Vivalis (NNYSE Euronext: VLS) says it has opened a new facility for partnered VIVA|Screen…

BiotechnologyEuropeFinancialResearchSanofi PasteurVivalis

Global biotechnology market set to exceed $320 billion by 2015, says GIA

25-01-2012

The biotechnology industry was adversely affected by the global financial crisis, with several leading…

BiotechnologyGlobalMarkets & MarketingMergers & AcquisitionsResearch

A new year and good news is rolling in already, says AusBiotech

25-01-2012

Last year ended on a high for Australian biotechnology industry policy - with the R&D Tax Incentive up…

Asia-PacificBiotechnologyFinancialLicensing

Genzyme Framingham plant now cleared by US and EU regulators

24-01-2012

French drug major Sanofi (Euronext: SAN) said yesterday that the US Food and Drug Administration has…

BiotechnologyFabrazymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Rising interest of Big Pharma creates huge growth potential for outsourcing firms, says Frost & Sullivan

24-01-2012

Increasingly, big pharma is viewing the outsourcing of pharmaceutical manufacturing as a strategic move…

BiotechnologyEuropeFinancialMarkets & MarketingPharmaceutical

Spectrum upbeat on lymphoma drug Zevalin study

24-01-2012

US biotech firm Spectrum Pharmaceuticals (NasdaqGS: SPPI) yesterday announced results of a randomized…

BiotechnologyOncologyResearchSpectrum PharmaceuticalsZevalin

FDA lifts hold on Insmed Arikace trial

23-01-2012

USA-based biopharma company Insmed’s (Nasdaq CM: INSM) shares leapt 33.7% to $5.08 on Friday, after…

ArikaceBiotechnologyInsmedNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonary

Significant advances in biosimilar medicines claimed for Iran

23-01-2012

Iran is making significant advances in medicine production, especially in the fields of biosimilar and…

BiotechnologyGenericsMarkets & MarketingRest of the World

Thyroid cancer risk discovery by deCODE Genetics and collaborators

23-01-2012

Scientists at Iceland-based human genome specialist deCODE Genetics and academic collaborators from Iceland,…

BiotechnologydeCODE GeneticsOncologyResearch

EMA starts review of Gilenya; guidance on biosimilar interferon beta

23-01-2012

The European Medicines Agency has begun a review of the benefits and risks of Swiss drug major Novartis’…

BiotechnologyEuropeGenericsGilenyainterferon betaNeurologicalNovartisPharmaceuticalRegulation

FDA updates Tysabri label relating to anti-JCV

23-01-2012

The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

Alnylam looks to save $20 million via restructuring

22-01-2012

USA-based RNAi therapeutics specialist Alnylam Pharmaceuticals (Nasdaq: ALNY) said last week that it…

Alnylam PharmaceuticalsBiotechnologyFinancialManagement

Sandoz initiates two more Phase III biosimilar trials

20-01-2012

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone…

AmgenBiotechnologyFilgrastimGenericsNovartisOncologypegfilgrastimResearchSandozZarzio

FDA backs Gilead’s Viread for children

20-01-2012

The US Food and Drug Administration has approved US biotech firm Gilead Sciences (Nasdaq: GILD) Viread…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationViread

Which of 2012's launches will be future blockbusters?

20-01-2012

A review of the year's biggest product launches - based on analyst forecasts - reveals a bumper crop…

BiotechnologyFinancialPharmaceuticalRegulation

Activity of tesetaxel in advanced gastric cancer confirmed

19-01-2012

US antisense technology-based drug developer Genta (OTCBB: GNTA.OB) has announced positive results from…

BiotechnologyGentaOncologyResearchtesetaxel

BTG’s Voraxaze gains first approval, in USA

19-01-2012

The US Food and Drug Administration has approved UK headquartered BTG International’s (LSE: BGC)…

BiotechnologyBTGNephrology and HepatologyNorth AmericaOncologyRegulationVoraxaze

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Tufts CSDD establishes benchmarks for global CRAs

18-01-2012

The USA-based Tufts Center for the Study of Drug Development says that it has established the first global…

BiotechnologyNorth AmericaPharmaceuticalResearch

Roche in epigenetics drug discovery collaboration

18-01-2012

USA-based Constellation Pharmaceuticals says that it has entered into a major strategic agreement with…

BiotechnologyConstellation PharmaceuticalsGenentechLicensingMergers & AcquisitionsOncologyPharmaceuticalRoche

Aeras and CNBG in TB vaccine pact

18-01-2012

The global fight against the tuberculosis epidemic has received a boost as USA-based Aeras and the China…

AeresBiotechnologyChina National BiotecPharmaceuticalResearchRespiratory and PulmonaryVaccines

Zytiga overtaking Provenge in MCRPC

17-01-2012

Despite no current approval of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Zytiga (abiraterone)…

BiotechnologyDendreonJanssenJevtanaJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeSanofiZytiga

2001 to 2025 of 2253 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top